Amgen and Iovance Biotherapeutics present contrasting investment cases for 2026, with Amgen offering stability and Iovance offering high-risk growth potential. Amgen reported fiscal 2025 revenue of nearly $36.7 billion, a 9.9% increase, and net income of close to $7.7 billion, while Iovance posted revenue of approximately $263.5 million, a 60.6% jump, but a net loss of nearly $391.0 million. Amgen carries a debt-to-equity ratio of roughly 6.3x and generated free cash flow of close to $8.1 billion, whereas Iovance has a low debt-to-equity ratio of roughly 0.1x and negative free cash flow of close to $336.2 million. The author favors Amgen for its double-digit growth across sixteen brands, consistent dividend, and ability to navigate biosimilar competition, while noting Iovance's recent revenue miss and unprofitability make it suitable only for higher-risk investors.
Amgen IncAmgen reported strong fiscal 2025 revenue growth, net income, and free cash flow, with double-digit growth across sixteen brands and a consistent dividend.
Iovance Biotherapeutics IncIovance posted a net loss, negative free cash flow, and a recent revenue miss, making it unprofitable and high-risk.
